Cipla Aims to Sell Cheaper Versions of Expensive Biotech Medicines in India and China

Strategic Insights -

Indian drugmaker Cipla Ltd. plans to sell copies of Roche Holding AG and Amgen Inc.'s best-selling biotechnology medicines in China, marking a significant expansion in the country's biotech sector. Cipla Chairman Yusuf Hamied aims to invest in companies in India and Hong Kong that make monoclonal antibodies, a technology that will enable the Mumbai-based company to gain access to high-priced products such as Roche's Avastin and Herceptin cancer drugs and Amgen's rheumatoid arthritis treatment Enbrel. These three medications generated $19 billion in sales last year.

The strategy of copying medicines developed by others has helped Cipla become a major supplier of AIDS pills for developing nations. By selling biosimilars at lower prices, Cipla aims to make these high-priced medications more affordable for patients in India and China. This move is part of Cipla's efforts to tap into the growing demand for biotech medicines in emerging markets.

Key Takeaways:

  • Cipla plans to sell copies of Roche and Amgen's best-selling biotechnology medicines in China, including Avastin, Herceptin, and Enbrel, with the goal of making them more affordable for patients.
  • Cipla Chairman Yusuf Hamied aims to invest in companies in India and Hong Kong that make monoclonal antibodies, enabling the company to access high-priced products.
  • The three medications generated $19 billion in sales last year, presenting a significant revenue opportunity for Cipla.
  • Cipla's strategy of creating biosimilars has helped the company become a major supplier of AIDS pills for developing nations.
  • Cipla plans to target 8-10 treatments for rheumatoid arthritis, colorectal cancer, allergic asthma, and head and neck cancer that are not covered by patents in India and China.
  • Dr. Reddy's Laboratories Ltd. has already begun selling a version of rituximab, a cancer medicine, at about half the price of Roche's original, demonstrating the feasibility of the strategy.

Statistics:

  • $19 billion in sales generated by Avastin, Enbrel, and Herceptin last year (Roche and Amgen).
  • $30 billion in annual sales generated by the brand-name drugs that Cipla plans to target.
  • Cipla plans to invest $65 million over three years in companies that make monoclonal antibodies.
  • 40% of a company based in Goa and a 25% stake in a Hong Kong-based biotechnology company will be acquired by Cipla.

Sources:

  • "Cipla Aims to Sell Cheaper Versions of Expensive Biotech Medicines in India and China" by Euclid Infotech, distributed by Contify.com (2010)